Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in IntangiblesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Acquisitions (2023 - 2025)

Historic Acquisitions for Astrazeneca (AZNCF) over the last 4 years, with Q4 2025 value amounting to -$6.0 million.

  • Astrazeneca's Acquisitions changed N/A to -$6.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.1 billion, marking a year-over-year increase of 2598.34%. This contributed to the annual value of -$66.0 million for FY2025, which is 9761.82% up from last year.
  • Per Astrazeneca's latest filing, its Acquisitions stood at -$6.0 million for Q4 2025.
  • Astrazeneca's Acquisitions' 5-year high stood at -$6.0 million during Q4 2025, with a 5-year trough of -$2.0 billion in Q2 2024.
  • Moreover, its 3-year median value for Acquisitions was -$457.5 million (2023), whereas its average is -$741.5 million.
  • Within the past 5 years, the most significant YoY rise in Astrazeneca's Acquisitions was 28412.7% (2024), while the steepest drop was 28412.7% (2024).
  • Quarter analysis of 3 years shows Astrazeneca's Acquisitions stood at -$189.0 million in 2023, then tumbled by 982.01% to -$2.0 billion in 2024, then surged by 99.71% to -$6.0 million in 2025.
  • Its Acquisitions stands at -$6.0 million for Q4 2025, versus -$2.0 billion for Q2 2024 and -$726.0 million for Q1 2024.